PDCD1 and mature T-cell and NK-cell non-Hodgkin lymphoma: The disappointing results of anti-PD1 ICIs in PTCL, NOS in combination with the risk of hyperprogression in a third of treated patients led to the termination of studies with ICIs in PTCL, NOS.